The FDA recently approved a subcutaneous version of J&J's blood cancer drug Darzalex.
This approval probably won't significantly impact J&J overall due to the company's size and potential cannibalization of sales from the current version of Darzalex.
J&J's small partner that contributed key technology for the new Darzalex version could be the big winner.
